{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T08:44:36Z","timestamp":1772095476493,"version":"3.50.1"},"reference-count":34,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2024,6,26]],"date-time":"2024-06-26T00:00:00Z","timestamp":1719360000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100014717","name":"National Outstanding Youth Science Fund Project of National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["30901744"],"award-info":[{"award-number":["30901744"]}],"id":[{"id":"10.13039\/100014717","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Clin Pharmacol"],"published-print":{"date-parts":[[2024,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Aims<\/jats:title><jats:p>The recommended dosage of pegylated recombinant human granulocyte\u2010colony stimulating factor (PEG\u2010rhG\u2010CSF) for Western chemotherapy patients is 6\u00a0mg per cycle. However, for Eastern Asians, the optimal dose remains unknown.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This open\u2010label, randomized, non\u2010inferiority trial (NCT05283616) enrolled Chinese female breast cancer patients receiving adjuvant chemotherapy. Participants were randomized to receive either 3 or 6\u00a0mg of PEG\u2010rhG\u2010CSF per cycle, stratified by body weight (BW; \u226460\u2009kg <jats:italic>vs<\/jats:italic>. &gt;60\u2009kg). The primary endpoint was timely absolute neutrophil count (ANC) recovery before the second cycle of chemotherapy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 122 patients were randomized and 116 were included for efficacy analyses. The timely ANC recovery rate in the 3\u00a0mg arm was 89.8%, compared to 93.0% in the 6\u00a0mg arm (one\u2010sided 95% confidence interval [CI] lower limit for difference: \u221211.7%), meeting the prespecified non\u2010inferiority margin of 15%. The rate was 93.3% with PEG\u2010rhG\u2010CSF 3\u00a0mg and 96.6% with 6\u00a0mg in patients with BW\u2009\u2264\u200960\u2009kg, and 86.2% and 89.3%, respectively, in those with BW\u2009&gt;\u200960\u2009kg. Although the incidence of severe neutropenia was similar across arms, the occurrence of excessively high ANC and white blood cell counts was higher in the 6\u00a0mg arm. No grade \u22653 adverse events related to PEG\u2010rhG\u2010CSF occurred.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Three milligrams of PEG\u2010rhG\u2010CSF per cycle provided non\u2010inferior neutrophil protection and attenuated neutrophil overshoot compared to 6\u00a0mg doses. This low\u2010dose regimen could be a new supportive care option for Chinese breast cancer patients receiving anthracycline\u2010based adjuvant chemotherapy.<\/jats:p><\/jats:sec>","DOI":"10.1111\/bcp.16151","type":"journal-article","created":{"date-parts":[[2024,6,26]],"date-time":"2024-06-26T23:34:17Z","timestamp":1719444857000},"page":"2621-2629","source":"Crossref","is-referenced-by-count":2,"title":["Low\u2010dose pegylated recombinant human granulocyte\u2010colony stimulating factor as hematopoietic support for adjuvant chemotherapy in Chinese patients with breast cancer: An open\u2010label, randomized, non\u2010inferiority trial"],"prefix":"10.1111","volume":"90","author":[{"given":"Sheng","family":"Yang","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital Chinese Academy of Medical Sciences and Peking Union Medical College  Beijing China"},{"name":"Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs  Beijing China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shan\u2010shan","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital Chinese Academy of Medical Sciences and Peking Union Medical College  Beijing China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chang\u2010gong","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital Chinese Academy of Medical Sciences and Peking Union Medical College  Beijing China"},{"name":"Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs  Beijing China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying\u2010lei","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital Chinese Academy of Medical Sciences and Peking Union Medical College  Beijing China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meng","family":"Xiu","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital Chinese Academy of Medical Sciences and Peking Union Medical College  Beijing China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8903-3666","authenticated-orcid":false,"given":"Pin","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital Chinese Academy of Medical Sciences and Peking Union Medical College  Beijing China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2024,6,26]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2010.10.013"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.01.008"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V88.6.1907.bloodjournal8861907"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdg019"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1097\/CAD.0b013e3283610b5d"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.issn.0253\u20103766.2016.01.005"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.20.3.727"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280\u2010018\u20103607\u20107"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1177\/0897190019838374"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyw152"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.13607"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.12740"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2014.01.002"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6604862"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1177\/009286159903300422"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1177\/009286159903300424"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520\u2010014\u20102597\u20101"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520\u2010015\u20102654\u20104"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1208\/s12248\u2010018\u20100249\u2010y"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270006288731"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.13.2522"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.2165\/11586040\u2010000000000\u201000000"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10637\u2010014\u20100068\u20107"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1586\/era.11.72"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.05.7174"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdn051"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.02.8621"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12885\u2010023\u201011198\u20102"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.1177\/1060028017706373"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.1185\/030079907X219599"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.3816\/CBC.2003.n.003"},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.06.4451"},{"key":"e_1_2_11_34_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.18.4028"},{"key":"e_1_2_11_35_1","doi-asserted-by":"publisher","DOI":"10.1159\/000449226"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.16151","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,19]],"date-time":"2025-06-19T04:04:13Z","timestamp":1750305853000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/bcp.16151"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,26]]},"references-count":34,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["10.1111\/bcp.16151"],"URL":"https:\/\/doi.org\/10.1111\/bcp.16151","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,26]]}}}